Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Brain Neoplasms 5Neoplasms 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Supratentorial Neoplasms 1Stomach Neoplasms 1Seizures 1Prostatic Neoplasms 1Postoperative Complications 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Ovarian Cysts 1Neoplasm Metastasis 1Myofibroma 1Liver Neoplasms 1Hematologic Diseases 1Endobronchial Metastases 1Encephalocele 1Ear Neoplasms 1Cholecystitis 1Breast Neoplasms 1Brain Injuries 1

Interventions

Sorafenib 68Bevacizumab 44Oxaliplatin 25Doxorubicin 22Gemcitabine 21Fluorouracil 21Radiosurgery 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17lenvatinib 17Cisplatin 17Capecitabine 17atezolizumab 14Leucovorin 14Hepatectomy 14Radiotherapy 12tremelimumab 10Irinotecan 10Drug Therapy 10Cyclophosphamide 10Carboplatin 10Blood Specimen Collection 10Ipilimumab 9regorafenib 8Liver Transplantation 8Everolimus 8Cryosurgery 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × Remifentanil × Clear all
NCT06003218 2025-04-02

Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation

Peking University First Hospital

Phase NA Completed
88 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡